For hereditary hemochromatosis, the European Association for the Study of the Liver recommends pausing phlebotomy when hemoglobin falls below 11 g/dL (110 g/L) and reducing treatment frequency below 12 g/dL (120 g/L). These thresholds are not universal: in polycythemia vera, clinicians generally guide phlebotomy by hematocrit—the percentage of blood made up of red cells—rather than a hemoglobin cutoff.
Therapeutic phlebotomy, also called venesection, involves removing blood to reduce excess iron or an excessive number of red blood cells. Because removing blood also reduces the body's red blood cell supply, healthcare professionals monitor blood counts during treatment. The level at which treatment is delayed, adjusted, or stopped depends on the condition being treated, the patient's response, and the clinical protocol being followed.
When should hemoglobin be too low for phlebotomy?
For people receiving phlebotomy for hereditary hemochromatosis, European guidance provides two useful thresholds. The European Association for the Study of the Liver (EASL) recommends reducing the frequency of blood removal when hemoglobin falls below 12 g/dL (120 g/L). If it falls below 11 g/dL (110 g/L), phlebotomy should be discontinued temporarily while blood tests and clinical findings are reassessed.
These thresholds are intended to help prevent excessive blood removal and the development of iron deficiency or anemia. They are guidance for managing hemochromatosis, not universal stopping rules for every condition treated with phlebotomy. A treatment center may use an individualized protocol based on the patient's health, laboratory results, and tolerance of previous sessions.
Why does the reason for phlebotomy matter?
The appropriate stopping point depends on what treatment is intended to achieve. According to Cleveland Clinic, therapeutic phlebotomy is commonly used for hereditary hemochromatosis, which involves excess iron storage, and polycythemia vera, a disorder in which the bone marrow produces too many red blood cells. These conditions require different laboratory targets, so the same hemoglobin result does not automatically mean the same thing for both patients.
Phlebotomy for hereditary hemochromatosis
In hereditary hemochromatosis, the primary goal is to remove excess iron stored in the body. Hemoglobin is monitored to ensure that repeated blood removal does not excessively reduce the red blood cell supply. Ferritin, a blood marker that reflects stored iron, helps clinicians assess how much iron remains and whether treatment is approaching its intended target.
The Mayo Clinic guidance on hemochromatosis treatment explains that blood removal is initially performed more frequently to lower iron levels, followed by less frequent maintenance treatment when appropriate. If hemoglobin approaches the treatment team's safety threshold, the immediate question is whether another session can be performed safely, even if iron stores still require treatment.
Temporarily stopping because hemoglobin is too low does not necessarily mean that iron overload has been fully treated. Once the reason for the low result has been assessed and blood counts have recovered sufficiently, the clinician may consider resuming treatment. The timing and amount of blood removed should be individualized.
Phlebotomy for polycythemia vera
Polycythemia vera requires a different approach. The main laboratory goal is usually to control hematocrit, which measures the percentage of blood volume occupied by red blood cells, rather than to stop phlebotomy at a particular hemoglobin level.
According to American Family Physician, phlebotomy for polycythemia vera is generally directed toward maintaining hematocrit below 45% to reduce the risk of blood clots. This target is specific to the management of polycythemia vera. It should not be interpreted as a universal target for people receiving phlebotomy for excess iron or other conditions.
Hemoglobin and hematocrit are related measurements, but they are not interchangeable. A clinician may review both, along with the complete blood count and the patient's overall response, when deciding whether another session is appropriate. There is no single hemoglobin number that automatically ends phlebotomy for every person with polycythemia vera.
Does stopping phlebotomy mean treatment is finished?
Not necessarily. There is an important difference between temporarily withholding a session because of a low hemoglobin level and completing the initial course of treatment because the intended laboratory target has been reached.
For hereditary hemochromatosis, the EASL guidance uses ferritin targets to assess iron removal: below 50 micrograms per liter during the initial iron-removal phase and below 100 micrograms per liter during maintenance treatment. These are treatment targets for appropriately diagnosed hemochromatosis, not values that readers should use to manage their own treatment.
After the initial treatment phase, some people need periodic maintenance phlebotomy because iron stores can rise again. Others may require a different schedule. A temporary pause because hemoglobin is low and a decision to move to maintenance treatment are therefore separate clinical decisions.
What blood tests are checked before another session?
Healthcare professionals use laboratory results to assess both treatment progress and the safety of further blood removal. Depending on the condition, monitoring may include:
- Hemoglobin: Measures the oxygen-carrying protein in red blood cells and helps identify a reduction that may make another session unsuitable.
- Complete blood count: Provides additional information about red blood cells and other blood cells.
- Ferritin: Helps assess iron stores when phlebotomy is used for hereditary hemochromatosis.
- Hematocrit: Measures the proportion of blood made up of red blood cells and is particularly important when treating polycythemia vera.
MedlinePlus explains that the timing of phlebotomy for hemochromatosis depends on factors including hemoglobin, serum ferritin, symptoms, and iron intake. Results should be reviewed together rather than used in isolation to make treatment decisions.
When a hemoglobin result is lower than expected or has fallen compared with previous tests, the treating clinician may reassess the blood count, iron status, symptoms, and recent treatment history. The clinician can then determine whether to postpone the next session, change the amount of blood removed, adjust the interval between sessions, or investigate another reason for the change.
What should you do if your hemoglobin falls near the stopping threshold?
Contact the healthcare professional or treatment center managing your phlebotomy before proceeding with another session if you have been told that your hemoglobin is approaching or below the center's limit. Do not assume that a previous treatment schedule remains appropriate after a meaningful change in your blood count.
It is also important not to start iron supplements simply because hemoglobin has fallen without discussing the result with your clinician, particularly when phlebotomy is being used to treat iron overload. The clinician should establish why the level has changed and whether the treatment plan needs adjustment.
Seek prompt medical assessment if you develop concerning symptoms such as marked weakness, persistent dizziness, fainting, chest pain, or shortness of breath. Chest pain, severe breathing difficulty, or fainting with ongoing symptoms may require emergency care.
The key point is that hemoglobin below 11 g/dL (110 g/L) is a recognized temporary stopping threshold in EASL guidance for hereditary hemochromatosis, while a level below 12 g/dL (120 g/L) may prompt less frequent treatment. For polycythemia vera and other indications, the clinician must use the target and safety criteria appropriate to the condition being treated.